Portland, OR, April 25, 2019 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the Europe IVD market was estimated at $20.1 billion in 2017 and is expected to hit $26.6 billion by 2023, growing at a CAGR of 4.7% from 2017 to 2023. The report offers an in-depth analysis of evolving market trends, top investment pockets, key segments, drivers & opportunities, and competitive landscape.
Request Report Sample at: https://www.alliedmarketresearch.com/request-sample/4352
Rising incidence of chronic & infectious diseases, technological advancements in IVD, emergence of minimal invasive technologies, increasing government expenditures on healthcare, and surge in popularity of personalized medicine approach have fueled the growth of the Europe IVD market. On the other hand, vague reimbursement policies and stringent regulatory schemes have happened to curb the growth to some extent. However, potential opportunities for outsourcing and convergence of new technologies have paved the way for multiple opportunities in the segment.
Based on product type, the reagents segment accounted for nearly three-fifth of the total market in 2017 and is expected to dominate till 2023. On the other hand, the instruments segment is anticipated to grow at the fastest CAGR of 6.1% during the forecast period.
Based on technology, the immunodiagnostics segment held the largest share, contributing to nearly one-third of the total market in 2017 and is anticipated to retain its top status throughout the study period. Simultaneously, the hematology segment is showcased as the fastest growing sector with a CAGR of 5.7% throughout 2017-2023.
Based on application, the infectious diseases segment accounted for more than one-fourth of the total market and is assumed to be dominant till 2023. The cancer segment, on the other hand, is estimated to grow at the fastest CAGR of 6.6% during the period.
Do Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/4352
Key market players studied in the research include Alere Inc., Danaher Corporation, F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Sysmex Corporation, Becton Dickinson and Company, Johnson & Johnson, Bio-Rad Laboratories, Biomerieux, and Bayer AG. They have adopted a number of high-end stratagems to maintain their status in the market.
About Us:
Allied Market Research (AMR) is a full-service market research and business -consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.